default author photo

Birgit Geoerger

Gustave Roussy

Villejuif

France

SCHOLARLY PAPERS

3

DOWNLOADS

213

TOTAL CITATIONS

0

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Chemo-Immunotherapy with Dinutuximab Beta in Patients with Progressive High-Risk Neuroblastoma: Does Chemotherapy Backbone Matter?

Number of pages: 18 Posted: 30 Jan 2024
Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoit Dumont, Anne-Sophie Desfachelles, Estelle Thebaud, Julie Tandonnet, C. Pasqualini, Stéphanie Proust, Natacha Entz-Werle, Isabelle Aerts, Lee Aymar Ndounga-Diakou, Arnaud Petit, Chloe Puiseux, Leslie Andry, Jeremie Rouger, Ludovic Mansuy, Joy Benadiba, Frédéric Millot, Claire Pluchart, Salim Laghouati, Birgit Geoerger, Gilles Vassal, Dominique Valteau-Couannet and Pablo Berlanga
Gustave Roussy, PSL Research University - Institut Curie, Toulouse University Hospital, Institut d’Hématologie et d’Oncologie Pédiatrique (iHOPe) - Centre Léon Bérard, University of Lille II - Centre Oscar Lambret, Pediatric Immuno-Hemato-Oncology Unit, CHU Nantes, University of Bordeaux - CHU de Bordeaux, Gustave Roussy, University Hospital of Fort de France, Les Hôpitaux Universitaires de Strasbourg, PSL Research University - Institut Curie, Gustave Roussy, AP-HP Hôpital Trousseau, Université de Rennes 1 - Rennes University Hospital, Amiens Picardie University Hospital, University Hospital, Caen, Children's Hospital of Brabois, Nice University Hospital, Université de Poitiers - Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire Reims (CHU Reims), Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy and Gustave Roussy
Downloads 108 (649,907)

Abstract:

Loading...

Neuroblastoma, immunotherapy, dinutuximab beta, chemotherapy, relapse, real-world data.

2.

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Downloads 95 (715,072)

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Number of pages: 28 Posted: 14 Apr 2022
Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne-Sophie Desfachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J. Brisse, Gudrun Schleiermacher, olivier delattre, Gaelle Pierron and Daniel Orbach
PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, Clocheville Hospital - Pediatric Onco-Hematology Service, Aix-Marseille University - Assistance Publique-Hopitaux de Marseille, Gustave Roussy, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, Université d'Amiens - Department of Oncology-Hematology and Pediatric Immunology, University of Strasbourg - Department of Hematology and Oncology, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, University of Lille II - Centre Oscar Lambret, PSL Research University - Institut Curie, Gustave Roussy, University of Claude Bernard Lyon 1 - Centre Léon Bérard, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie and PSL Research University - SIREDO Oncology Center
Downloads 53 (1,049,673)

Abstract:

Loading...

Neurotrophic Tropomyosin Receptor Kinase, Fusion Transcript Tumor, TRK Inhibitor, Infantile Fibrosarcoma, burden of therapy.

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

Number of pages: 20 Posted: 10 May 2022
Lauriane Lemelle, Delphine Guillemot, Anne-Laure Hermann, Arnaud Gauthier, Matthieu Carton, Nadège Corradini, Angélique Rome, Pablo Berlanga, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, Hélène Boutroux, Anne-Sophie Desfachelles, Isabelle Aerts, Birgit Geoerger, Marie Karanian, François Doz, Hervé J. Brisse, Gudrun Schleiermacher, olivier delattre, Gaelle Pierron and Daniel Orbach
PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, Clocheville Hospital - Pediatric Onco-Hematology Service, Aix-Marseille University - Assistance Publique-Hopitaux de Marseille, Gustave Roussy, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, Université d'Amiens - Department of Oncology-Hematology and Pediatric Immunology, University of Strasbourg - Department of Hematology and Oncology, Hospital Sant Joan de Deu - Department of Pediatric Hematology and Oncology, University of Lille II - Centre Oscar Lambret, PSL Research University - Institut Curie, Gustave Roussy, University of Claude Bernard Lyon 1 - Centre Léon Bérard, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie, PSL Research University - Institut Curie and PSL Research University - SIREDO Oncology Center
Downloads 42 (1,183,247)

Abstract:

Loading...

Neurotrophic Tropomyosin Receptor Kinase, Fusion Transcript Tumor, TRK Inhibitor, Infantile Fibrosarcoma, burden of therapy.

3.

Eligibility criteria in pediatric oncology Phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium

Number of pages: 37 Posted: 29 Mar 2026
Uri Ilan, Alba Rubio-San-Simón, Natasha van Eijkelenburg, Cormac Owens, Aviva Kraus, L. Moreno, Fernando Carceller, Carole Lecinse, Leona Knox, Nicole Scobie, Birgit Geoerger, C. Michel Zwaan, Pamela Kearns and F. Bautista
Princess Maxima Center for Pediatric Oncology, Hospital Infantil Universitario Niño Jesús, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Gustave Roussy, Princess Máxima Center for Pediatric Oncology, University of Birmingham - NIHR Birmingham Biomedical Research Centre and Institute of Cancer and Genomic Sciences and affiliation not provided to SSRN
Downloads 10 (1,541,665)

Abstract:

Loading...

Clinical Trials, pediatric hematology and oncology, drug development, access to innovation, equity, eligibility criteria, inclusion, exclusion, phase I, phase II